AKT1 and melanoma: We have been the first to show that activation of the ErbB3/AKT axis in melanoma can be inhibited by co-treatment with anti-ErbB3 mAbs and that these antibodies synergize with BRAF and MEK inhibitors in short term in vitro clonogenic assays [27].